ACET 📈 Adicet Bio - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0070021086
ACET: Gamma Delta T Cell, CAR Therapies, Cancer, Autoimmune Diseases
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. Web URL: https://www.adicetbio.com
Additional Sources for ACET Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACET Stock Overview
| Market Cap in USD | 76m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Health Care Distributors |
| IPO / Inception | 2018-01-26 |
ACET Stock Ratings
| Growth 5y | -89.1% |
| Fundamental | -62.2% |
| Dividend | - |
| Rel. Strength Industry | -2558 |
| Analysts | 4.43/5 |
| Fair Price Momentum | 0.54 USD |
| Fair Price DCF | - |
ACET Dividends
No Dividends PaidACET Growth Ratios
| Growth Correlation 3m | -81.7% |
| Growth Correlation 12m | -85.6% |
| Growth Correlation 5y | -70.9% |
| CAGR 5y | -38.36% |
| CAGR/Mean DD 5y | -0.70 |
| Sharpe Ratio 12m | -1.25 |
| Alpha | -100.76 |
| Beta | 1.35 |
| Volatility | 94.17% |
| Current Volume | 414.4k |
| Average Volume 20d | 567k |
What is the price of ACET stocks?
As of January 15, 2025, the stock is trading at USD 0.91 with a total of 414,352 shares traded.
Over the past week, the price has changed by -19.76%, over one month by -9.35%, over three months by -36.62% and over the past year by -70.85%.
As of January 15, 2025, the stock is trading at USD 0.91 with a total of 414,352 shares traded.
Over the past week, the price has changed by -19.76%, over one month by -9.35%, over three months by -36.62% and over the past year by -70.85%.
Is Adicet Bio a good stock to buy?
No, based on ValueRay Fundamental Analyses, Adicet Bio (NASDAQ:ACET) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -62.23 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACET as of January 2025 is 0.54. This means that ACET is currently overvalued and has a potential downside of -40.66%.
No, based on ValueRay Fundamental Analyses, Adicet Bio (NASDAQ:ACET) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -62.23 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACET as of January 2025 is 0.54. This means that ACET is currently overvalued and has a potential downside of -40.66%.
Is ACET a buy, sell or hold?
Adicet Bio has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy ACET.
Adicet Bio has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy ACET.
- Strong Buy: 5
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for ACET stock price target?
According to ValueRays Forecast Model, ACET Adicet Bio will be worth about 0.6 in January 2026. The stock is currently trading at 0.91. This means that the stock has a potential downside of -34.07%.
According to ValueRays Forecast Model, ACET Adicet Bio will be worth about 0.6 in January 2026. The stock is currently trading at 0.91. This means that the stock has a potential downside of -34.07%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6.4 | 603.3% |
| Analysts Target Price | 20.3 | 2134.1% |
| ValueRay Target Price | 0.6 | -34.1% |